The UK government has partnered with BioNTech to conduct trials of personalised mRNA-based cancer immunotherapies. These trials aim to provide precision immunotherapies to treat cancer patients and offer personalized treatments for up to 10,000 patients by 2030. BioNTech will establish a regional hub and labs in Cambridge, staffed with over 70 highly skilled scientists. The collaboration will also involve the creation of a Cancer Vaccine Launch Pad (CVLP) to identify eligible patients for potential trials. Clinical trials have already begun, with further enrollment expected from 2026 onwards.
